These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

615 related articles for article (PubMed ID: 16323095)

  • 21. Clinical efficacy of moxifloxacin in the treatment of bacterial keratitis: a randomized clinical trial.
    Constantinou M; Daniell M; Snibson GR; Vu HT; Taylor HR
    Ophthalmology; 2007 Sep; 114(9):1622-9. PubMed ID: 17822972
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.
    Lucasti C; Jasovich A; Umeh O; Jiang J; Kaniga K; Friedland I
    Clin Ther; 2008 May; 30(5):868-83. PubMed ID: 18555934
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate.
    Lipsky BA; Giordano P; Choudhri S; Song J
    J Antimicrob Chemother; 2007 Aug; 60(2):370-6. PubMed ID: 17553812
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of moxifloxacin for treatment of penicillin-, macrolide- and multidrug-resistant Streptococcus pneumoniae in community-acquired pneumonia.
    Fogarty C; Torres A; Choudhri S; Haverstock D; Herrington J; Ambler J
    Int J Clin Pract; 2005 Nov; 59(11):1253-9. PubMed ID: 16236076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens.
    Dunbar LM; Khashab MM; Kahn JB; Zadeikis N; Xiang JX; Tennenberg AM
    Curr Med Res Opin; 2004 Apr; 20(4):555-63. PubMed ID: 15119993
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative analysis of length of stay, total costs, and treatment success between intravenous moxifloxacin 400 mg and levofloxacin 750 mg among hospitalized patients with community-acquired pneumonia.
    Friedman H; Song X; Crespi S; Navaratnam P
    Value Health; 2009; 12(8):1135-43. PubMed ID: 19695010
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia.
    File TM; Milkovich G; Tennenberg AM; Xiang JX; Khashab MM; Zadeikis N
    Curr Med Res Opin; 2004 Sep; 20(9):1473-81. PubMed ID: 15383197
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Levofloxacin versus beta-lactamic therapy in community acquired pneumonia that requires hospitalization].
    Geijo Martínez MP; Díaz de Tuesta Chow-Quan AM; Herranz CR; Gómez Criado C; Dimas Nuñez JF; Saiz García F
    An Med Interna; 2002 Dec; 19(12):621-5. PubMed ID: 12593029
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicentre randomized, double-blind studies.
    Ortiz-Ruiz G; Vetter N; Isaacs R; Carides A; Woods GL; Friedland I
    J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii59-66. PubMed ID: 15150184
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical experience with moxifloxacin in patients with respiratory tract infections.
    Faich GA; Morganroth J; Whitehouse AB; Brar JS; Arcuri P; Kowalsky SF; Haverstock DC; Celesk RA; Church DA
    Ann Pharmacother; 2004 May; 38(5):749-54. PubMed ID: 15026565
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis.
    Schwab IR; Friedlaender M; McCulley J; Lichtenstein SJ; Moran CT;
    Ophthalmology; 2003 Mar; 110(3):457-65. PubMed ID: 12623805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia.
    Pertel PE; Bernardo P; Fogarty C; Matthews P; Northland R; Benvenuto M; Thorne GM; Luperchio SA; Arbeit RD; Alder J
    Clin Infect Dis; 2008 Apr; 46(8):1142-51. PubMed ID: 18444848
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Moxifloxacin five-day therapy versus placebo in acute bacterial rhinosinusitis.
    Hadley JA; Mösges R; Desrosiers M; Haverstock D; van Veenhuyzen D; Herman-Gnjidic Z
    Laryngoscope; 2010 May; 120(5):1057-62. PubMed ID: 20422704
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An open-label, randomized comparison of levofloxacin and amoxicillin/clavulanate plus clarithromycin for the treatment of hospitalized patients with community-acquired pneumonia.
    Lin TY; Lin SM; Chen HC; Wang CJ; Wang YM; Chang ML; Wang CH; Liu CY; Lin HC; Yu CT; Hsieh LL; Kuo HP; Huang CD
    Chang Gung Med J; 2007; 30(4):321-32. PubMed ID: 17939262
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Moxifloxacin versus levofloxacin for treatment of acute rhinosinusitis: a retrospective database analysis of treatment duration, outcomes, and charges.
    Keating KN; Friedman HS; Perfetto EM
    Curr Med Res Opin; 2006 Feb; 22(2):327-33. PubMed ID: 16466604
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical efficacy and safety of moxifloxacin versus levofloxacin plus metronidazole for community-acquired pneumonia with aspiration factors.
    Sun T; Sun L; Wang R; Ren X; Sui DJ; Pu C; Ren Y; Liu Y; Yang Z; Li F
    Chin Med J (Engl); 2014; 127(7):1201-5. PubMed ID: 24709166
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Moxifloxacin vs amoxicillin/clavulanate in the treatment of acute sinusitis.
    Arrieta JR; Galgano AS; Sakano E; Fonseca X; Amábile-Cuevas CF; Hernández-Oliva G; Vivar R; González G; Torres A;
    Am J Otolaryngol; 2007; 28(2):78-82. PubMed ID: 17362810
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis.
    Starakis I; Gogos CA; Bassaris H
    Int J Antimicrob Agents; 2004 Feb; 23(2):129-37. PubMed ID: 15013037
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral clindamycin 300 mg BID compared with oral amoxicillin/clavulanic acid 1 g BID in the outpatient treatment of acute recurrent pharyngotonsillitis caused by group a beta-hemolytic streptococci: an international, multicenter, randomized, investigator-blinded, prospective trial in patients between the ages of 12 and 60 years.
    Mahakit P; Vicente JG; Butt DI; Angeli G; Bansal S; Zambrano D
    Clin Ther; 2006 Jan; 28(1):99-109. PubMed ID: 16490583
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults.
    Ortiz-Ruiz G; Caballero-Lopez J; Friedland IR; Woods GL; Carides A;
    Clin Infect Dis; 2002 Apr; 34(8):1076-83. PubMed ID: 11914996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.